Lixte Biotechnology (LIXT) Competitors $2.63 +0.61 (+30.15%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$2.38 -0.25 (-9.66%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. CLDI, APLM, ORGS, PMCB, SLXN, CVM, OMGA, CELZ, AIM, and INDPShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Calidi Biotherapeutics (CLDI), Apollomics (APLM), Orgenesis (ORGS), Nuvilex (PMCB), Silexion Therapeutics (SLXN), CEL-SCI (CVM), Omega Therapeutics (OMGA), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Calidi Biotherapeutics Apollomics Orgenesis Nuvilex Silexion Therapeutics CEL-SCI Omega Therapeutics Creative Medical Technology AIM ImmunoTech Indaptus Therapeutics Lixte Biotechnology (NASDAQ:LIXT) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk. Do insiders and institutionals have more ownership in LIXT or CLDI? 5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 14.8% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, LIXT or CLDI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLixte BiotechnologyN/AN/A-$3.59M-$1.45-1.81Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Which has more volatility & risk, LIXT or CLDI? Lixte Biotechnology has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Does the media favor LIXT or CLDI? In the previous week, Lixte Biotechnology had 10 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 11 mentions for Lixte Biotechnology and 1 mentions for Calidi Biotherapeutics. Lixte Biotechnology's average media sentiment score of 0.06 beat Calidi Biotherapeutics' score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Calidi Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LIXT or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Lixte BiotechnologyN/A N/A -189.35% Calidi Biotherapeutics N/A N/A -344.45% SummaryLixte Biotechnology beats Calidi Biotherapeutics on 5 of the 7 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.05M$2.88B$5.50B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-1.8121.5627.5520.29Price / SalesN/A245.31389.87112.84Price / CashN/A41.9536.6357.47Price / Book-2.217.518.075.68Net Income-$3.59M-$55.05M$3.17B$249.04M7 Day Performance267.90%4.61%2.83%3.30%1 Month Performance89.14%4.89%3.70%5.20%1 Year Performance13.32%5.84%35.41%21.37% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.9369 of 5 stars$2.63+30.1%N/A+13.3%$7.05MN/A-1.814News CoverageGap UpHigh Trading VolumeCLDICalidi Biotherapeutics0.226 of 5 stars$0.23+2.8%N/AN/A$7.31M$50K0.0038Gap UpAPLMApollomics0.3704 of 5 stars$6.56+0.8%N/A-65.8%$7.18M$1.49M0.0045Positive NewsORGSOrgenesis1.8891 of 5 stars$1.48-1.7%N/AN/A$7.08M$662K0.00150Gap DownPMCBNuvilex0.9495 of 5 stars$1.09+5.8%N/A-45.2%$7.07MN/A1.474Positive NewsSLXNSilexion TherapeuticsN/A$0.81+1.4%$5.00+517.3%N/A$6.95MN/A0.00N/ACVMCEL-SCI0.3196 of 5 stars$2.29-4.6%N/A-92.4%$6.94MN/A-4.7743OMGAOmega Therapeutics2.1687 of 5 stars$0.13-21.8%$8.50+6,700.0%-93.4%$6.92M$8.10M-0.09120Gap UpCELZCreative Medical Technology0.9739 of 5 stars$2.65flatN/A-29.8%$6.85M$10K-0.705Positive NewsAIMAIM ImmunoTech2.0324 of 5 stars$8.65-2.8%$275.00+3,079.2%-76.9%$6.80M$146K-18.4020Gap UpINDPIndaptus Therapeutics3.4135 of 5 stars$10.53-9.5%$238.00+2,160.2%-82.5%$6.66MN/A-0.256Gap Down Related Companies and Tools Related Companies CLDI Alternatives APLM Alternatives ORGS Alternatives PMCB Alternatives SLXN Alternatives CVM Alternatives OMGA Alternatives CELZ Alternatives AIM Alternatives INDP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
